What is ABSI's market cap?

$1.61B, based on the Nov 5 close of $9.39.

Does Absci pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ABSI is sold short?

37.0M shares, 31.0% of float, as of Oct 15, 2026.

What sector is ABSI in?

Technology, in the R&D — Physical & Biological Sciences industry.

NASDAQ · ABSITechnologyR&D — Physical & Biological Sciences

Absci Corporation Common Stock (ABSI)

$9.39−10.40%

Close Nov 5, 2026 · split-adjusted

Nov 5, 2026$9.39▲ 146.46% in range

Nov 5, 2025Low $2.30 · High $12.10Nov 5, 2026

What changed · written from our data

As of Nov 5, 2026

Absci closed at $9.39 on Nov 5, down 10.40%, 22.4% below its 52-week closing high. Volume of 5.1M shares was 1.34× its 20-day average (above normal).

Split-adjusted performance: +1.8% over one month, +63.3% over six months, +138.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $318K, down 46.4% from a year earlier, with a net margin of -10443.4%.

Short interest was 37.0M shares at the Oct 15 settlement, down 1.1% from the prior report (31.0% of float, 9.0 days to cover).

Market cap$1.61B171.6M shares

Revenue · quarter$318.0K−46.4% YoY

Diluted EPS$-0.21—

P/E · TTM—P/S 1,032.3×

Net margin-10,443.4%Gross 100.0%

Dividend yieldNone

52-week range2.30 – 12.10−22.4% from high

Volume5.1M1.34× 20-day avg

Volatility · 60d103.2%Annualised

Short % of float31.0%9.0 days to cover

Net cash$201.0MCash $201.1M

Next earnings—Not scheduled

Split-adjusted performance

1W −22.4%1M +1.8%3M +5.2%6M +63.3%YTD +169.1%1Y +138.3%3Y +622.3%5Y −34.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within R&D — Physical & Biological Sciences

Percentile among 11 companies (100 = best)

6-month momentum80

Revenue growth10

Net margin0

Value (low P/E)—

Size60

Industry medians: 6-month return +48.1%, revenue growth +8.5%, net margin −122.0%, P/E 47.0×.

Short interest

Details →

Shares short37.0M−1.1% vs prior

Days to cover9.0Settled Oct 15

% of float31.0%

Short vol. 10d50.4%of daily volume

Closest peers by size in R&D — Physical & Biological Sciences

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ABSIAbsci	$9.39	−10.40%	+63.3%	−46.4%	−10443.4%	—	$1.61B
OABIOmniAb	$4.83	−6.76%	+228.6%	+78.3%	−393.9%	—	$704.5M	Compare
NRCNRC Health	$25.48	−5.87%	+36.0%	+11.0%	12.3%	88.2	$540.7M	Compare
CRLCharles River Laboratories International	$313.02	−4.07%	+72.3%	−2.7%	−0.1%	—	$15.00B	Compare
MEDPMedpace Holdings	$634.98	−3.32%	+48.1%	+8.5%	19.2%	34.3	$17.76B	Compare
MXCTMaxCyte	$1.31	−5.76%	+50.3%	−14.5%	−122.0%	—	$135.2M	Compare
INCYIncyte Genomics	$118.01	−3.94%	+20.7%	+14.0%	−50.4%	59.6	$24.05B	Compare
IQVIQVIA Holdings	$264.88	+0.41%	+48.3%	+8.0%	7.9%	31.3	$43.65B	Compare
IBACIB Acquisition	$10.81	−0.46%	−0.2%	—	—	—	$54.1M	Compare

News about Absci

All news →

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · May 5, 2026Neutral Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical OfficerGlobeNewswire Inc. · Mar 3, 2026▲ Positive

Quick answers

What does Absci do?: Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
What is ABSI's market cap?: $1.61B, based on the Nov 5 close of $9.39.
Does Absci pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ABSI is sold short?: 37.0M shares, 31.0% of float, as of Oct 15, 2026.
What sector is ABSI in?: Technology, in the R&D — Physical & Biological Sciences industry.

About Absci

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.

HQ: Vancouver, WA140 employeesListed Jul 22, 2021absci.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology